Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 26, 2018
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
1-3619
13-5315170
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
235 East 42nd Street
New York, New York 
(Address of principal executive offices)
 
10017 
(Zip Code)
Registrant's telephone number, including area code:
(212) 733-2323

Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
[   ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐



Item 5.07
Submission of Matters to a Vote of Security Holders
(a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 26, 2018.
 
(b) Shareholders voted on the matters set forth below.
1.  The nominees for election to the Company’s Board of Directors were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes:
 
 
 
 
 
 
Nominee
Votes For
 Votes Against
Abstentions
Broker non-vote
 
Dennis A. Ausiello
4,108,728,641
79,882,319
11,520,427
923,139,453
 
Ronald E. Blaylock
4,102,046,338
81,670,030
16,414,332
923,139,453
 
Albert Bourla
4,066,124,646
122,714,120
11,292,006
923,139,453
 
W. Don Cornwell
3,984,735,073
201,815,697
13,572,919
923,139,453
 
Joseph J. Echevarria
4,009,427,816
128,789,526
61,914,045
923,139,453
 
Helen H. Hobbs
4,158,460,045
31,222,644
10,447,449
923,139,453
 
James M. Kilts
4,025,819,403
162,514,018
11,797,816
923,139,453
 
Dan R. Littman
4,155,203,205
33,499,038
11,428,230
923,139,453
 
Shantanu Narayen
4,121,708,670
66,768,599
11,643,247
923,139,453
 
Suzanne Nora Johnson
4,065,134,950
124,218,718
10,766,918
923,139,453
 
Ian C. Read
3,970,452,334
199,049,638
30,624,121
923,139,453
 
James C. Smith
4,133,648,657
52,974,916
13,507,065
923,139,453
 



2.  The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2018 fiscal year was approved based upon the following votes:
 
 
 
Votes for approval
4,938,011,334
 
Votes against
170,765,860
 
Abstentions
14,484,272
 
Broker non-votes
n/a
 
 
 
 
3. The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers was approved based upon the following votes:
 
 
 
Votes for approval
3,865,836,269
 
Votes against
307,749,940
 
Abstentions
26,544,915
 
Broker non-votes
923,139,453
 
 
 
 
 
 
 
4. The proposal to approve the Pfizer Inc. French Sub-Plan under the 2014 Stock Plan was approved based upon the following votes:
 
 
 
Votes for approval
4,009,297,297
 
Votes against
156,668,597
 
Abstentions
34,165,493
 
Broker non-votes
923,139,453
 
 
 
 
5. The shareholder proposal regarding right to act by written consent was not approved based upon the following votes:
 
 
 
Votes for approval
1,509,956,494
 
Votes against
2,656,246,000
 
Abstentions
33,927,896
 
Broker non-votes
923,139,453
 
 
 
 
6. The shareholder proposal regarding independent chair policy was not approved based upon the following votes:
 
 
 
Votes for approval
1,067,768,186
 
Votes against
3,103,947,589
 
Abstentions
28,415,466
 
Broker non-votes
923,139,453
 
 
 
 
 
 
 


7. The shareholder proposal regarding report on lobbying activities was not approved based upon the following votes:
 
 
 
Votes for approval
1,363,371,782
 
Votes against
2,710,672,755
 
Abstentions
126,085,108
 
Broker non-votes
923,139,453
 
 
 
 
(c) Not applicable
 
 
(d) Not applicable
 
 





SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.


 
 
PFIZER INC.
 
 
 
Dated: May 1, 2018
 
By:   /s/ Margaret M. Madden
         Margaret M. Madden
 
 
  Title: Senior Vice President & Corporate Secretary
          Chief Governance Counsel